Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


GREY:CLAZF - Post by User

Comment by PTBaileyon Sep 16, 2021 11:49am
77 Views
Post# 33868591

RE:RE:RE:RE:RE:Seen this all before with Kalytera. Option to aquire=0

RE:RE:RE:RE:RE:Seen this all before with Kalytera. Option to aquire=0
Dude51 wrote: What ever, go to Claritas investors site and read what the investor scientist said about CLAS. Then come back and tell us what you think. Seeing the non news again today affirms my belief this stock is BS. 


I looked at the articles you reference, they are 10 to 15 years old. I would think the technology and science on this has changed somewhat in tha time, would it not?

You also pulled this quote out on that site, "a recent meta-analysis of 16 clinical trials of prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors in severe pulmonary arterial hypertension (PAH) from 1990 to 2005 shows that although the pharmacological agents moderately improve symptoms and hemodynamic parameters, none significantly reduces mortality (13). These disappointing results are not predicted by animal model studies, which show these classes of drugs largely prevent, and in some cases reverse, chronic hypoxia- and monocrotaline-induced pulmonary hypertension in rats (e.g., 6, 25, 29, 30). "

With the many advances in the medical and scientific field I don't thing we can consider research from 1990 to 2005 recent.

To save people the trouble of searching here are the links.

https://journals.physiology.org/doi/full/10.1152/ajplung.00281.2007
https://www.atsjournals.org/doi/full/10.1164/rccm.200502-296OC
https://erj.ersjournals.com/content/37/4/813.short 
<< Previous
Bullboard Posts
Next >>